Identification of RAD17 as a candidate cancer predisposition gene in families with histories of pancreatic and breast cancers.
DNA damage repair genes
Genetic predisposition
Pancreatic cancer
Whole exome sequencing
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
13 Jun 2024
13 Jun 2024
Historique:
received:
20
06
2023
accepted:
28
05
2024
medline:
14
6
2024
pubmed:
14
6
2024
entrez:
13
6
2024
Statut:
epublish
Résumé
Among the 10% of pancreatic cancers that occur in a familial context, around a third carry a pathogenic variant in a cancer predisposition gene. Genetic studies of pancreatic cancer predisposition are limited by high mortality rates amongst index patients and other affected family members. The genetic risk for pancreatic cancer is often shared with breast cancer susceptibility genes, most notably BRCA2, PALB2, ATM and BRCA1. Therefore, we hypothesized that additional shared genetic etiologies might be uncovered by studying families presenting with both breast and pancreatic cancer. Focusing on a multigene panel of 276 DNA Damage Repair (DDR) genes, we performed next-generation sequencing in a cohort of 41 families with at least three breast cancer cases and one pancreatic cancer. When the index patient with pancreatic cancer was deceased, close relatives (first or second-degree) affected with breast cancer were tested (39 families). We identified 27 variants of uncertain significance in DDR genes. A splice site variant (c.1605 + 2T > A) in the RAD17 gene stood out, as a likely loss of function variant. RAD17 is a checkpoint protein that recruits the MRN (MRE11-RAD50-NBS1) complex to initiate DNA signaling, leading to DNA double-strand break repair. Within families with breast and pancreatic cancer, we identified RAD17 as a novel candidate predisposition gene. Further genetic studies are warranted to better understand the potential pathogenic effect of RAD17 variants and in other DDR genes.
Sections du résumé
BACKGROUND
BACKGROUND
Among the 10% of pancreatic cancers that occur in a familial context, around a third carry a pathogenic variant in a cancer predisposition gene. Genetic studies of pancreatic cancer predisposition are limited by high mortality rates amongst index patients and other affected family members. The genetic risk for pancreatic cancer is often shared with breast cancer susceptibility genes, most notably BRCA2, PALB2, ATM and BRCA1. Therefore, we hypothesized that additional shared genetic etiologies might be uncovered by studying families presenting with both breast and pancreatic cancer.
METHODS
METHODS
Focusing on a multigene panel of 276 DNA Damage Repair (DDR) genes, we performed next-generation sequencing in a cohort of 41 families with at least three breast cancer cases and one pancreatic cancer. When the index patient with pancreatic cancer was deceased, close relatives (first or second-degree) affected with breast cancer were tested (39 families).
RESULTS
RESULTS
We identified 27 variants of uncertain significance in DDR genes. A splice site variant (c.1605 + 2T > A) in the RAD17 gene stood out, as a likely loss of function variant. RAD17 is a checkpoint protein that recruits the MRN (MRE11-RAD50-NBS1) complex to initiate DNA signaling, leading to DNA double-strand break repair.
CONCLUSION
CONCLUSIONS
Within families with breast and pancreatic cancer, we identified RAD17 as a novel candidate predisposition gene. Further genetic studies are warranted to better understand the potential pathogenic effect of RAD17 variants and in other DDR genes.
Identifiants
pubmed: 38872153
doi: 10.1186/s12885-024-12442-z
pii: 10.1186/s12885-024-12442-z
doi:
Substances chimiques
DNA-Binding Proteins
0
Cell Cycle Proteins
0
NBN protein, human
0
Nuclear Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
723Informations de copyright
© 2024. The Author(s).
Références
Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology. 2020;159(1):335–49. e15.
doi: 10.1053/j.gastro.2020.02.068
pubmed: 32247694
Ferlay J, Partensky C, Bray F. More deaths from pancreatic cancer than breast cancer in the EU by 2017. Acta Oncol. 2016;55(9–10):1158–60.
doi: 10.1080/0284186X.2016.1197419
pubmed: 27551890
Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016;388(10039):73–85.
doi: 10.1016/S0140-6736(16)00141-0
pubmed: 26830752
Hassan MM, Bondy ML, Wolff RA, Abbruzzese JL, Vauthey JN, Pisters PW, et al. Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol. 2007;102(12):2696–707.
doi: 10.1111/j.1572-0241.2007.01510.x
pubmed: 17764494
pmcid: 2423805
Kirkegard J, Mortensen FV, Cronin-Fenton D. Chronic pancreatitis and pancreatic cancer risk: a systematic review and meta-analysis. Am J Gastroenterol. 2017;112(9):1366–72.
doi: 10.1038/ajg.2017.218
pubmed: 28762376
Guerra C, Schuhmacher AJ, Canamero M, Grippo PJ, Verdaguer L, Perez-Gallego L, et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell. 2007;11(3):291–302.
doi: 10.1016/j.ccr.2007.01.012
pubmed: 17349585
Carriere C, Young AL, Gunn JR, Longnecker DS, Korc M. Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras. Biochem Biophys Res Commun. 2009;382(3):561–5.
doi: 10.1016/j.bbrc.2009.03.068
pubmed: 19292977
pmcid: 2927854
Llach J, Carballal S, Moreira L. Familial pancreatic cancer: current perspectives. Cancer Manag Res. 2020;12:743–58.
doi: 10.2147/CMAR.S172421
pubmed: 32099470
pmcid: 6999545
Petersen GM. Familial pancreatic cancer. Semin Oncol. 2016;43(5):548–53.
doi: 10.1053/j.seminoncol.2016.09.002
pubmed: 27899186
pmcid: 5234085
ASCO. Familial pancreatic cancer. [ https://www.cancer.net/cancer-types/familial-pancreatic-cancer
Goggins M, Overbeek KA, Brand R, Syngal S, Del Chiaro M, Bartsch DK, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the international cancer of the pancreas screening (CAPS) consortium. Gut. 2020;69(1):7–17.
doi: 10.1136/gutjnl-2019-319352
pubmed: 31672839
Bennett C, Suguitan M, Abad J, Chawla A. Identification of high-risk germline variants for the development of pancreatic cancer: common characteristics and potential guidance to screening guidelines. Pancreatology. 2022;22(6):719–29.
doi: 10.1016/j.pan.2022.05.005
pubmed: 35798629
Panchoo AV, VanNess GH, Rivera-Rivera E, Laborda TJ. Hereditary pancreatitis: an updated review in pediatrics. World J Clin Pediatr. 2022;11(1):27–37.
doi: 10.5409/wjcp.v11.i1.27
pubmed: 35096544
pmcid: 8771313
Solomon S, Das S, Brand R, Whitcomb DC. Inherited pancreatic cancer syndromes. Cancer J. 2012;18(6):485–91.
doi: 10.1097/PPO.0b013e318278c4a6
pubmed: 23187834
pmcid: 3565835
Golan T, Varadhachary GR, Sela T, Fogelman DR, Halperin N, Shroff RT, et al. Phase II study of olaparib for BRCAness phenotype in pancreatic cancer. J Clin Oncol. 2018;36(4suppl):297.
doi: 10.1200/JCO.2018.36.4_suppl.297
Ghiorzo P. Genetic predisposition to pancreatic cancer. World J Gastroenterol. 2014;20(31):10778–89.
doi: 10.3748/wjg.v20.i31.10778
pubmed: 25152581
pmcid: 4138458
Tan M, Brusgaard K, Gerdes AM, Mortensen MB, Detlefsen S, Schaffalitzky de Muckadell OB, et al. Whole genome sequencing identifies rare germline variants enriched in cancer related genes in first degree relatives of familial pancreatic cancer patients. Clin Genet. 2021;100(5):551–62.
doi: 10.1111/cge.14038
pubmed: 34313325
pmcid: 9291090
Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, et al. Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas. Cell Rep. 2018;23(1):239–e546.
doi: 10.1016/j.celrep.2018.03.076
pubmed: 29617664
pmcid: 5961503
Lopacinska-Joergensen J, Oliveira D, Poulsen TS, Hoegdall CK, Hoegdall EV. Somatic variants in DNA damage response genes in ovarian cancer patients using whole-exome sequencing. Anticancer Res. 2023;43(5):1891–900.
doi: 10.21873/anticanres.16348
pubmed: 37097678
Dalmasso B, Puccini A, Catalano F, Borea R, Iaia ML, Bruno W et al. Beyond BRCA: the emerging significance of DNA damage response and personalized treatment in pancreatic and prostate cancer patients. Int J Mol Sci. 2022;23(9).
Arora S, Balasubramaniam S, Zhang H, Berman T, Narayan P, Suzman D, et al. FDA approval summary: olaparib monotherapy or in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer. Oncologist. 2021;26(1):e164–72.
doi: 10.1002/onco.13551
pubmed: 33017510
Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30(4):558–66.
doi: 10.1093/annonc/mdz012
pubmed: 30689707
pmcid: 6503629
Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317–27.
doi: 10.1056/NEJMoa1903387
pubmed: 31157963
pmcid: 6810605
Byrum AK, Vindigni A, Mosammaparast N. Defining and modulating ‘BRCAness’. Trends Cell Biol. 2019;29(9):740–51.
doi: 10.1016/j.tcb.2019.06.005
pubmed: 31362850
MSigDB v5. 0 [ http://software.broadinstitute.org/gsea/msigdb/collections.jsp
Pearl LH, Schierz AC, Ward SE, Al-Lazikani B, Pearl FM. Therapeutic opportunities within the DNA damage response. Nat Rev Cancer. 2015;15(3):166–80.
doi: 10.1038/nrc3891
pubmed: 25709118
Bell JC, Kowalczykowski SC. Mechanics and single-molecule interrogation of DNA recombination. Annu Rev Biochem. 2016;85:193–226.
doi: 10.1146/annurev-biochem-060614-034352
pubmed: 27088880
Kowalczykowski SC. An overview of the molecular mechanisms of recombinational DNA repair. Cold Spring Harb Perspect Biol. 2015;7(11).
Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, et al. REVEL: an ensemble method for predicting the pathogenicity of rare missense variants. Am J Hum Genet. 2016;99(4):877–85.
doi: 10.1016/j.ajhg.2016.08.016
pubmed: 27666373
pmcid: 5065685
Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C, Evans JP, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med. 2017;19(2):249–55.
doi: 10.1038/gim.2016.190
pubmed: 27854360
Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46(D1):D1062–7.
doi: 10.1093/nar/gkx1153
pubmed: 29165669
Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285–91.
doi: 10.1038/nature19057
pubmed: 27535533
pmcid: 5018207
Jiang H, Huang F, Chen X, Zhang L, Shen M, Pan B et al. Germline mutations in homologous recombination repair genes among Chinese pancreatic ductal adenocarcinoma patients detected using next-generation sequencing. Mol Genet Genomic Med. 2023:e2170.
Shen JP, Srivas R, Gross A, Li J, Jaehnig EJ, Sun SM, et al. Chemogenetic profiling identifies RAD17 as synthetically lethal with checkpoint kinase inhibition. Oncotarget. 2015;6(34):35755–69.
doi: 10.18632/oncotarget.5928
pubmed: 26437225
pmcid: 4742139
Cheng J, Demeulemeester J, Wedge DC, Vollan HKM, Pitt JJ, Russnes HG, et al. Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors. Nat Commun. 2017;8(1):1221.
doi: 10.1038/s41467-017-01355-0
pubmed: 29089486
pmcid: 5663922
Wang Q, Goldstein M, Alexander P, Wakeman TP, Sun T, Feng J, et al. Rad17 recruits the MRE11-RAD50-NBS1 complex to regulate the cellular response to DNA double-strand breaks. EMBO J. 2014;33(8):862–77.
doi: 10.1002/embj.201386064
pubmed: 24534091
pmcid: 4194111
Fukumoto Y, Ikeuchi M, Nakayama Y, Ogra Y. Rad17 translocates to nucleolus upon uv irradiation through nucleolar localization signal in the central basic domain. Int J Mol Sci. 2022;23(20).
Kciuk M, Gielecinska A, Mujwar S, Mojzych M, Kontek R. Cyclin-dependent kinases in DNA damage response. Biochim Biophys Acta Rev Cancer. 2022;1877(3):188716.
doi: 10.1016/j.bbcan.2022.188716
pubmed: 35271993
Lee KY, Park SH. Eukaryotic clamp loaders and unloaders in the maintenance of genome stability. Exp Mol Med. 2020;52(12):1948–58.
doi: 10.1038/s12276-020-00533-3
pubmed: 33339954
pmcid: 8080817
Bagnoli M, Nicoletti R, Valitutti M, Rizzo A, Napoli A, De Montalvao R, et al. Impairment of RAD17 functions by mir-506-3p as a novel synthetic lethal approach targeting DNA repair pathways in ovarian cancer. Front Oncol. 2022;12:923508.
doi: 10.3389/fonc.2022.923508
pubmed: 35924161
pmcid: 9340372
Tsao CC, Geisen C, Abraham RT. Interaction between human MCM7 and Rad17 proteins is required for replication checkpoint signaling. EMBO J. 2004;23(23):4660–9.
doi: 10.1038/sj.emboj.7600463
pubmed: 15538388
pmcid: 533049
Blaikley EJ, Tinline-Purvis H, Kasparek TR, Marguerat S, Sarkar S, Hulme L, et al. The DNA damage checkpoint pathway promotes extensive resection and nucleotide synthesis to facilitate homologous recombination repair and genome stability in fission yeast. Nucleic Acids Res. 2014;42(9):5644–56.
doi: 10.1093/nar/gku190
pubmed: 24623809
pmcid: 4027169
Aguirre AJ, Nowak JA, Camarda ND, Moffitt RA, Ghazani AA, Hazar-Rethinam M, et al. Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine. Cancer Discov. 2018;8(9):1096–111.
doi: 10.1158/2159-8290.CD-18-0275
pubmed: 29903880
pmcid: 6192263
Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17(4):500–3.
doi: 10.1038/nm.2344
pubmed: 21460848
pmcid: 3755490
Lowery MA, Jordan EJ, Basturk O, Ptashkin RN, Zehir A, Berger MF, et al. Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype. Clin Cancer Res. 2017;23(20):6094–100.
doi: 10.1158/1078-0432.CCR-17-0899
pubmed: 28754816
Payliss BJ, Patel A, Sheppard AC, Wyatt HDM. Exploring the structures and functions of macromolecular SLX4-nuclease complexes in genome stability. Front Genet. 2021;12:784167.
doi: 10.3389/fgene.2021.784167
pubmed: 34804132
pmcid: 8599992
He Y, Yuan C, Chen L, Lei M, Zellmer L, Huang H et al. Transcriptional-readthrough RNAs reflect the phenomenon of a gene contains gene(s) or gene(s) within a gene in the human genome, and thus are not chimeric RNAs. Genes (Basel). 2018;9(1).